Premium
Mutation analysis of CDP , TP53 , and KRAS in uterine leiomyomas
Author(s) -
Patrikis Maria I.,
Bryan Emma J.,
Thomas Nicola A.,
Rice Greg E.,
Quinn Michael A.,
Baker Mark S.,
Campbell Ian G.
Publication year - 2003
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.10127
Subject(s) - biology , uterine leiomyoma , kras , exon , germline mutation , germline , somatic cell , gene , genetics , epigenetics , p14arf , leiomyoma , mutation , cancer research , heteroduplex , tumor suppressor gene , microbiology and biotechnology , carcinogenesis , uterus , pathology , medicine
Leiomyomas are the most common gynecologic tumors in women, but very little is known about their molecular pathology. We used single‐stranded conformational polymorphism/heteroduplex analysis to analyze 42 unselected uterine leiomyomas for somatic mutations in all coding exons of the gene encoding CCAAT displacement protein (CDP), as well as exons 5–8 of TP53 and codons 1–36 and 38–80 of KRAS . No somatic mutations were identified in either TP53 or KRAS , indicating that disregulation of these genes is not required for leiomyomas development. Aberrant band shifts were identified in CDP , but these were all germline nonpathogenic variants that have been reported previously. There is good functional and genetic evidence indicating that CDP is a leiomyoma suppressor, but our data suggested that somatic mutations in this gene were rare in unselected uterine leiomyomas. It is possible that CDP belongs to a class of tumor suppressor in which loss of only one copy of the gene, either by genetic or epigenetic mechanisms, is sufficient to allow tumor growth. © 2003 Wiley‐Liss, Inc.